Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of XmAb27564 in Patients With Plaque Psoriasis and Atopic Dermatitis

NCT06005792 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT06005792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of XmAb27564 in Patients With Plaque Psoriasis and Atopic Dermatitis
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 10, 2022
Completion date
November 22, 2024
Enrollment
23 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, psoriasis